Search Results  for '4174.TWO'

Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

OBI Pharma Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

30 Apr 2016 Reuters Investment Profile 12 $20.00

Thomson Reuters Stock Report - OBI Pharma Inc (4174-OT)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

29 Apr 2016 Thomson Reuters Stock Report 11 $25.00

OBI Pharma, Inc. (4174) - Financial Analysis Review

OBI Pharma, Inc. (4174) - Financial Analysis Review Summary OBI Pharma, Inc. (OBI Pharma) is a biopharmaceutical company. The...

18 Apr 2016 GlobalData 38 $300.00

OBI Pharma Inc. (4174 TT): ASCO Accepted OBI’s Data Submission

OBI unblinded its OBI-822 Phase 2/3 clinical trials in TPEx on February 21st, 2016, and OBI-822 did not show a statistically ...

07 Apr 2016 MasterLink Securities Corporation 8 $81.00

浩鼎 (4174):踏出一步,ASCO接受浩鼎申請

回歸生技產業發展,尊重學術專業,靜待6/3 ASCO數據發表:浩鼎在2/21於櫃買中心公布其解盲未達主要療效指標統計意義後,由於浩鼎須遵從ASCO規範不得提前公布數據,亦產生眾多非基本面議論,進而使評價受到影響,亦連帶影響其他生技醫療類股。基於風險考...

31 Mar 2016 MasterLink Securities Corporation 7 $58.00

生技醫療: 中裕愛滋病新藥TMB-355授權Theratechnologies

重要訊息 中裕(4147 TT, NT$209.0, 未評等)愛滋病新藥TMB-355與加拿大Theratechnologies簽12年獨家銷售契約,未來銷售中裕可取得52%銷售金額外,另還有前期金(upfront payment)與哩程金(mil...

21 Mar 2016 KGI Greater China 3 $12.00

OBI Pharma, Inc. (4174) - Financial Analysis Review

OBI Pharma, Inc. (4174) - Financial Analysis Review Summary OBI Pharma, Inc. (OBI Pharma) is a biopharmaceutical company. The...

16 Mar 2016 GlobalData 38 $300.00

OBI Pharma Inc. (4174 TT): OBI Has Launched Many Initiatives Despite Headwind

In our view, given the trial results of TFDA Phase 2/3 show no statistical significance, before the disclosure of detailed da...

24 Feb 2016 MasterLink Securities Corporation 9 $92.00

OBI Pharma Inc. (4174 TT): No Statistically Significant Difference

In our view, given the trial results of TFDA Phase 2/3 show no statistically significant difference, OBI needs to re-arrange ...

23 Feb 2016 MasterLink Securities Corporation 3 $23.00

浩鼎 (4174):無畏風雨,全面啟動

考量法規面尚未通過,以及仍需至6/3始有詳細數據揭露,元富在短期仍具眾多考驗下於21日下調至中立評等,然仍建議留意國際癌症免疫療法潛在價值:元富認為,由於TFDA phaseII/III臨床並未達顯著標準,在未具有詳細數據進一步判讀前,考量風險將評價...

22 Feb 2016 MasterLink Securities Corporation 7 $58.00